NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

John A. Thompson; Bryan J. Schneider; Julie Brahmer; Stephanie Andrews; Philippe Armand; Shailender Bhatia; Lihua E. Budde; Luciano Costa; Marianne Davies; David Dunnington; Marc S. Ernstoff; Matthew Frigault; Benjamin H. Kaffenberger; Matthew Lunning; Suzanne McGettigan; Jordan McPherson; Nisha A. Mohindra; Jarushka Naidoo; Anthony J. Olszanski; Olalekan Oluwole; Sandip P. Patel; Nathan Pennell; Sunil Reddy; Mabel Ryder; Bianca Santomasso; Scott Shofer; Jeffrey A. Sosman; Yinghong Wang; Ryan M. Weight; Alyse Johnson-Chilla; Griselda Zuccarino-Catania; Anita Engh

Journal ArticleOPEN ACCESS

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Thompson J
Schneider B
Brahmer J
et al.

Journal of the National Comprehensive Cancer Network (2020) 18(3) 230-241

DOI: 10.6004/jnccn.2020.0012

N/ACitations

91Readers

Abstract

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.

Cite

CITATION STYLE

APA

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., … Engh, A. (2020). NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network, 18(3), 230–241. https://doi.org/10.6004/jnccn.2020.0012

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Abstract

Cite

Register to see more suggestions